ATA329284A - Verfahren zur herstellung eines arzneimittels zur behandlung von virusinfektionen - Google Patents

Verfahren zur herstellung eines arzneimittels zur behandlung von virusinfektionen

Info

Publication number
ATA329284A
ATA329284A AT0329284A AT329284A ATA329284A AT A329284 A ATA329284 A AT A329284A AT 0329284 A AT0329284 A AT 0329284A AT 329284 A AT329284 A AT 329284A AT A329284 A ATA329284 A AT A329284A
Authority
AT
Austria
Prior art keywords
producing
medicinal product
virus infections
treating virus
treating
Prior art date
Application number
AT0329284A
Other languages
English (en)
Other versions
AT392081B (de
Inventor
Akira Kaji
Original Assignee
Akira Kaji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP58192350A external-priority patent/JPH0740934B2/ja
Priority claimed from JP59049321A external-priority patent/JPS60193922A/ja
Application filed by Akira Kaji filed Critical Akira Kaji
Publication of ATA329284A publication Critical patent/ATA329284A/de
Application granted granted Critical
Publication of AT392081B publication Critical patent/AT392081B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT0329284A 1983-10-17 1984-10-16 Verfahren zur herstellung eines arzneimittels zur behandlung von virusinfektionen AT392081B (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP58192350A JPH0740934B2 (ja) 1983-10-17 1983-10-17 ウイルス増殖阻害方法
JP59049321A JPS60193922A (ja) 1984-03-16 1984-03-16 抗ウイルス剤
MT957A MTP957B (en) 1983-10-17 1984-12-12 Method for inhibiting viral propagation and anti-viral agent

Publications (2)

Publication Number Publication Date
ATA329284A true ATA329284A (de) 1990-07-15
AT392081B AT392081B (de) 1991-01-25

Family

ID=39877713

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0329284A AT392081B (de) 1983-10-17 1984-10-16 Verfahren zur herstellung eines arzneimittels zur behandlung von virusinfektionen

Country Status (18)

Country Link
US (1) US4689320A (de)
AT (1) AT392081B (de)
AU (1) AU578625B2 (de)
BE (1) BE900827A (de)
CH (1) CH667593A5 (de)
DE (1) DE3437852A1 (de)
DK (1) DK168061B1 (de)
FR (1) FR2553420B1 (de)
GB (1) GB2148302B (de)
IE (1) IE57987B1 (de)
IT (1) IT1179144B (de)
LU (1) LU85594A1 (de)
MT (1) MTP957B (de)
NL (1) NL8403163A (de)
NZ (1) NZ209840A (de)
PH (1) PH21629A (de)
SE (1) SE466482B (de)
SG (1) SG31088G (de)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0477994B1 (de) * 1985-03-21 2001-06-13 Johnston, Stephen, Ph.D. Von Parasit gewonnener Widerstand
US5580716A (en) * 1985-03-21 1996-12-03 Stephen A. Johnston Parasite-derived resistance
NZ219834A (en) * 1986-04-02 1990-04-26 Pioneer Hi Bred Int Dna control sequence and viral gene combination suitable for plant cells
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5194428A (en) * 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5637573A (en) * 1986-05-23 1997-06-10 Agrawal; Sudhir Influenza virus replication inhibiting oligonucleotide analogues and their pharmaceutical compositions
US5834185A (en) * 1986-10-28 1998-11-10 Johns Hopkins University Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers which comprise pyrimidine analogs, triple helix complexes formed thereby and oligomers used in their formation
US4904582A (en) * 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
DE68929343T2 (de) * 1988-02-16 2002-09-12 Greatbatch Gen-Aid, Ltd. Modifizierte Zellen mit Resistenz gegen Retroviralinfektionen
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
ATE240401T1 (de) * 1989-03-21 2003-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5693622A (en) * 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
WO1990015814A1 (en) * 1989-06-20 1990-12-27 Meiogenics, Inc. Nuclease resistant, single-stranded, non-naturally occurring nucleic acid molecules
JPH05500217A (ja) * 1989-09-01 1993-01-21 テンプル　ユニバーシティ　―　オブ　ザ　コモンウェルス　システム　オブ　ハイヤー　エデュケーション ｃ―ａｂｌプロト―オンコ遺伝子に対するアンチセンスオリゴヌクレオチド
EP0500799B1 (de) * 1989-11-16 1998-01-14 Duke University Transformation von tierischen Hautzellen mit hilfe von Partikeln
US5177198A (en) * 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US7037646B1 (en) 1990-01-11 2006-05-02 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US6399754B1 (en) 1991-12-24 2002-06-04 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides
US5852182A (en) * 1990-01-11 1998-12-22 Isis Pharmaceuticals Inc. Thiol-derivatized oligonucleosides
US5872232A (en) * 1990-01-11 1999-02-16 Isis Pharmaceuticals Inc. 2'-O-modified oligonucleotides
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5859221A (en) * 1990-01-11 1999-01-12 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6395492B1 (en) * 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US20040142899A1 (en) * 1990-01-11 2004-07-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
AU651569B2 (en) * 1990-01-11 1994-07-28 Isis Pharmaceuticals, Inc. Compositions and methods for detecting and modulating RNA activity and gene expression
US6114513A (en) * 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
US5459255A (en) * 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US6005087A (en) * 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5514577A (en) * 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US5248670A (en) * 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
US6706694B1 (en) 1990-03-21 2004-03-16 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US6228844B1 (en) 1991-11-12 2001-05-08 Vical Incorporated Stimulating vascular growth by administration of DNA sequences encoding VEGF
US20030186913A1 (en) * 1990-03-21 2003-10-02 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
US5639595A (en) * 1990-05-01 1997-06-17 Isis Phamaceuticals, Inc. Identification of novel drugs and reagents
AU7906691A (en) * 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
JPH0813274B2 (ja) * 1990-08-13 1996-02-14 アイシス・ファーマシューティカルス・インコーポレーテッド 遺伝子発現を検出及び変調する糖修飾されたオリゴヌクレオチド
US6262241B1 (en) * 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
FI930628A7 (fi) * 1990-08-14 1993-03-24 Isis Pharmaceuticals Inc Influenssavirus tyypin A Ann Arbor-kannan H2N2 inhibointi antisense-ol igonukleotideillä
NZ239372A (en) * 1990-08-15 1997-06-24 Genta Inc Inhibition of herpes virus infection by antisense oligomers
US5595978A (en) * 1990-08-16 1997-01-21 Isis Pharmaceuticals, Inc. Composition and method for treatment of CMV retinites
CA2092711A1 (en) * 1990-09-21 1992-03-22 Laure Aurelian Compositions and methods for inhibiting growth or replication of viruses
AU8872191A (en) * 1990-09-21 1992-04-15 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Method of inhibiting viral production
US5942389A (en) * 1990-10-19 1999-08-24 Board Of Trustees Of The University Of Illinois Genes and genetic elements associated with sensitivity to cisplatin
US5532124A (en) * 1991-02-11 1996-07-02 Thomas Jefferson University Genetically engineered bacteria to identify and produce medically important agents
US5965722A (en) * 1991-05-21 1999-10-12 Isis Pharmaceuticals, Inc. Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
IL101978A0 (en) * 1991-05-31 1992-12-30 Genta Inc Neutral oligomers capable of being delivered transdermally and across mucous membranes
US6369209B1 (en) 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US7119184B2 (en) 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
AU3249793A (en) 1991-12-24 1993-07-28 Isis Pharmaceuticals, Inc. Compositions and methods for modulating beta -amyloid
US6033909A (en) * 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5643780A (en) * 1992-04-03 1997-07-01 Isis Pharmaceuticals, Inc. Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
US6521601B1 (en) * 1992-04-14 2003-02-18 Signal Pharmaceuticals, Inc. Method and composition for inhibition of viral replication
US6806084B1 (en) * 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
TW244371B (de) * 1992-07-23 1995-04-01 Tri Clover Inc
WO1994002499A1 (en) * 1992-07-27 1994-02-03 Hybridon, Inc. Oligonucleotide alkylphosphonothioates
US5985558A (en) 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
AU685074B2 (en) * 1992-12-14 1998-01-15 Start Technology Partnership Administration of oligonucleotides antisense to dopamine receptor MRNA for diagnosis and treatment of neurological pathologies
CN1122138A (zh) * 1993-01-21 1996-05-08 海布里顿公司 折回三螺旋形成寡核苷酸
US20040087521A1 (en) * 1993-03-18 2004-05-06 Merck & Co., Inc. Nucleic acid pharmaceuticals-influenza matrix
US5739309A (en) * 1993-07-19 1998-04-14 Gen-Probe Incorporated Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
WO1995003407A2 (en) * 1993-07-19 1995-02-02 Gen-Probe Incorporated Oligonucleotides with activity against human immunodeficiency virus
US6653458B1 (en) 1993-09-03 2003-11-25 Isis Pharmaceuticals, Inc. Modified oligonucleotides
DE69433036T2 (de) 1993-09-03 2004-05-27 Isis Pharmaceuticals, Inc., Carlsbad Aminoderivatisierte nukleoside und oligonukleoside
US5837852A (en) * 1993-10-14 1998-11-17 Bristol-Myers Squibb Company Capped nucleic acid oligomers that inhibit cap-dependent transcription of the influenza virus endonuclease
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
JPH10503364A (ja) * 1994-05-10 1998-03-31 ザ ジェネラル ホスピタル コーポレーション Ｃ型肝炎ウイルスのアンチセンス阻害
US5733781A (en) 1994-07-19 1998-03-31 Gen-Probe Incorporated Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
WO1996009832A1 (en) * 1994-09-29 1996-04-04 Nauchno-Proizvodstvennoe Predpriyatie 'farmek' Dna-rna hydrid and a dna preparation, methods of obtaining said hybrid and preparation from sturgeon milt, and a pharmaceutical compound based on said dna-rna hybrid
US6117993A (en) * 1995-05-23 2000-09-12 Hybridon, Inc. Synthons for oligonucleotide synthesis
US5750674A (en) * 1995-05-23 1998-05-12 Hybridon, Inc. Methods and compounds for the stereoselective enrichment of oligonucleotide diastereomers and oligonucleotides thereby produced
US5693773A (en) * 1995-06-07 1997-12-02 Hybridon Incorporated Triplex-forming antisense oligonucleotides having abasic linkers targeting nucleic acids comprising mixed sequences of purines and pyrimidines
US5856099A (en) * 1996-05-21 1999-01-05 Isis Pharmaceuticals, Inc. Antisense compositions and methods for modulating type I interleukin-1 receptor expression
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US5885834A (en) * 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US20040023917A1 (en) * 1996-12-31 2004-02-05 Bennett C. Frank Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7235653B2 (en) * 1996-12-31 2007-06-26 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
EP1012331B1 (de) 1997-07-01 2006-03-29 Isis Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
US20070149472A1 (en) * 1997-08-13 2007-06-28 Mckay Robert Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US6809193B2 (en) 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6306831B1 (en) 1997-09-12 2001-10-23 Qik Technologies, Inc. Transplacental delivery of oligonucleotides
US6232463B1 (en) 1997-10-09 2001-05-15 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
AUPP249298A0 (en) * 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
KR20010042069A (ko) * 1998-03-20 2001-05-25 베니텍 오스트레일리아 리미티드 유전자 발현 조절방법
CA2329252A1 (en) 1998-05-21 1999-11-25 Isis Pharmaceuticals Inc. Compositions and methods for topical delivery of oligonucleotides
AU745880B2 (en) 1998-05-21 2002-04-11 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US6277967B1 (en) 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US6015676A (en) * 1998-07-31 2000-01-18 Epiclone Inc. Method for knocking out gene transcripts by covalently binding of an anti-sense probe
KR100573231B1 (ko) * 1999-02-12 2006-04-24 상꾜 가부시키가이샤 신규 뉴클레오시드 및 올리고뉴클레오티드 유사체
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
JP4151751B2 (ja) * 1999-07-22 2008-09-17 第一三共株式会社 新規ビシクロヌクレオシド類縁体
US6423885B1 (en) * 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US20010011126A1 (en) * 1999-09-10 2001-08-02 Bock Elisabeth Marianne Neurogenic compositions and methods
AU2001276691A1 (en) * 2000-08-03 2002-02-18 Matsushita Electric Industrial Co., Ltd. Brushless motor and method of manufacturing the brushless motor
RU2172632C1 (ru) * 2000-12-01 2001-08-27 Каплина Элли Николаевна Способ получения иммунотропного противовирусного препарата
RU2188659C1 (ru) * 2001-04-20 2002-09-10 ООО Научно-производственное фармацевтическое предприятие "Полидан" Фармацевтическая композиция для терапии человека, обладающая иммунотропным действием
US20030096770A1 (en) * 2001-07-11 2003-05-22 Krotz Achim H. Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
US20030191075A1 (en) * 2002-02-22 2003-10-09 Cook Phillip Dan Method of using modified oligonucleotides for hepatic delivery
WO2004002416A2 (en) * 2002-06-26 2004-01-08 The Penn State Research Foundation Methods and materials for treating human papillomavirus infections
US20040009483A1 (en) * 2002-07-12 2004-01-15 Ilsley Diane D. Method of linear mRNA amplification using total RNA
AU2003273336A1 (en) * 2002-09-18 2004-04-08 Isis Pharmaceuticals, Inc. Efficient reduction of target rna's by single- and double-stranded oligomeric compounds
AU2003295387A1 (en) 2002-11-05 2004-06-03 Isis Parmaceuticals, Inc. Modified oligonucleotides for use in rna interference
WO2004071430A2 (en) * 2003-02-05 2004-08-26 University Of Massachusetts RNAi TARGETING OF VIRUSES
US8084432B2 (en) * 2003-02-13 2011-12-27 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of pouchitis
US7897582B2 (en) * 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7960355B2 (en) * 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
CA2569419A1 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US8101585B2 (en) * 2006-08-04 2012-01-24 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of JNK proteins
EP2432499A2 (de) 2009-05-20 2012-03-28 Schering Corporation Modulation von pilr-rezeptoren zur behandlung mikrobieller infektionen
US8691227B2 (en) 2009-12-17 2014-04-08 Merck Sharp & Dohme Corp. Methods of treating multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease using agonists antibodies to PILR-α
US9708360B2 (en) 2013-09-30 2017-07-18 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1107929A (en) * 1965-11-14 1968-03-27 Yissum Res Dev Co Organotin derivatives of natural and synthetic polymers
JPS5735516A (en) * 1980-08-11 1982-02-26 Yamasa Shoyu Co Ltd Agent for increasing radiosensitivity or agent for increasing effect of substance having activity similar to radiation
JPS5767518A (en) * 1980-09-17 1982-04-24 Yamasa Shoyu Co Ltd Radiosensitizing agent or agent for increasing effect of radiomimetic substance
US4511713A (en) * 1980-11-12 1985-04-16 The Johns Hopkins University Process for selectively controlling unwanted expression or function of foreign nucleic acids in animal or mammalian cells
US4394443A (en) * 1980-12-18 1983-07-19 Yale University Method for cloning genes
US4358586A (en) * 1980-12-23 1982-11-09 Harvey Rubin Detection and isolation of endorphin mRNA using a synthetic oligodeoxynucleotide
DE3106982A1 (de) * 1981-02-25 1982-09-09 Dr. Karl Thomae Gmbh, 7950 Biberach "neues tridecadeoxynukleotid, verfahren zu seiner herstellung und verwendung"
US4464359A (en) * 1981-04-10 1984-08-07 Research Corporation (2'-5')-Oligo (3'-deoxyadenylate) and derivatives thereof
ATE75483T1 (de) * 1981-10-23 1992-05-15 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
US4393201A (en) * 1981-11-04 1983-07-12 The Wistar Institute DNA Which codes for glycoprotein of era-strain rabies virus

Also Published As

Publication number Publication date
LU85594A1 (de) 1985-04-02
BE900827A (fr) 1985-02-15
GB2148302B (en) 1987-10-07
DK493584D0 (da) 1984-10-16
DE3437852A1 (de) 1985-05-23
NL8403163A (nl) 1985-05-17
FR2553420A1 (fr) 1985-04-19
SE8405133D0 (sv) 1984-10-15
AU3423984A (en) 1985-04-26
IT1179144B (it) 1987-09-16
SE466482B (sv) 1992-02-24
SG31088G (en) 1988-09-30
IE57987B1 (en) 1993-06-02
MTP957B (en) 1985-05-27
CH667593A5 (de) 1988-10-31
SE8405133L (sv) 1985-04-18
IE842668L (en) 1985-04-17
GB8425799D0 (en) 1984-11-21
US4689320A (en) 1987-08-25
AT392081B (de) 1991-01-25
IT8468021A0 (it) 1984-10-16
DK493584A (da) 1985-04-18
IT8468021A1 (it) 1986-04-16
AU578625B2 (en) 1988-11-03
PH21629A (en) 1987-12-11
DK168061B1 (da) 1994-01-31
GB2148302A (en) 1985-05-30
NZ209840A (en) 1988-11-29
FR2553420B1 (fr) 1988-04-01

Similar Documents

Publication Publication Date Title
ATA329284A (de) Verfahren zur herstellung eines arzneimittels zur behandlung von virusinfektionen
AT383271B (de) Verfahren zur herstellung von cerebralwirksamen arzneimitteln
DE3787596D1 (de) Verfahren zur behandlung eines glykosides.
DE59107098D1 (de) Verfahren zur Herstellung von Photopolymerplatten
ATA176783A (de) Verfahren zur behandlung eines blutgerinnungsfaktors viii-konzentrats
AT375016B (de) Verfahren zur herstellung eines mundpflegemittels
AT359639B (de) Verfahren zur herstellung eines praeparates zur behandlung von herpes zoster und anderen herpes-infektionen
AT376366B (de) Verfahren zur herstellung eines arzneimittels
AT371340B (de) Verfahren zur herstellung eines mittels zur behandlung von glaucom
DE69115615D1 (de) Verfahren zur Herstellung von Ethylenaminen
DE4291487T1 (de) Verfahren zur Herstellung von 4-Isothiazolin-3-on
AT389052B (de) Verfahren zur herstellung eines synergistischen arzneimittelpraeparates zur behandlung von leberkrankheiten
DE3485699D1 (de) Verfahren zur herstellung von filmen eines polymerisierten und amorphen halogensilans und nach diesem verfahren hergestellte produkte.
AT370286B (de) Verfahren zur herstellung eines medizinischdi[tetischen produktes
AT380005B (de) Verfahren zur herstellung von gipsprodukten
ATA213579A (de) Verfahren zur herstellung von neuen, diuretisch wirksamen steroid-spiro- oxazolidinon-derivaten en und von aus diesen verbindungen bereiteten arznei- mitteln
AT379295B (de) Verfahren zur herstellung eines fleischproduktes
AT369653B (de) Verfahren zur herstellung eines arzneipraeparates zur behandlung von krebs
DE69031780D1 (de) Verfahren zur Herstellung von (trans)-4-substituierten-DL-Prolinederivaten
DD208982A5 (de) Verfahren zur herstellung von emulsion/emulsionspolymeren
DE3853222D1 (de) Verfahren zur Behandlung eines photographischen Silberhalogenidmaterials.
ATA383882A (de) Verfahren zur herstellung oder behandlung von ferrochrom
AT382078B (de) Verfahren zur herstellung von praeparationen aus menschlichem blutplasma
ATA266988A (de) Verfahren zur behandlung von porzellanformen zur herstellung von tauchartikeln
AT387386B (de) Verfahren zur herstellung von kondensierten as-triazin-derivaten

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee
ELJ Ceased due to non-payment of the annual fee